Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
58 participants
INTERVENTIONAL
2016-04-30
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
so far it is known that lidocaine I.V do helps tinnitus but until now it is not clear if other means of drug delivery (e.g lidocaine patch) help tinnitus.
The investigators are going to compare 1 day of treatment with lidoderm patch cream Versus (VS.) tegaderm patch (containing no drug) in treating tinnitus patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus
NCT04192773
Cochlear Promontory Stimulation for Treatment of Tinnitus
NCT03759834
Treatment Evaluation of Neuromodulation for Tinnitus - Stage A3
NCT05227365
External Therapy for Tinnitus Management
NCT07017998
Attenuation of Tonal Tinnitus by Lateral Inhibition Therapy
NCT04807686
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
first the investigators are going to invite tinnitus patients for the first visit.
the participants will get full explanation about the trial. in the first visit the investigators will confirm that the participants are suitable for the trial -
1. no exclusion criteria are present
2. the participant will perform 2 screening tests-
* minimental state examination (MMSE) to evaluate patients cognitive ability to participate in this trial. performance under 24 points is an exclusion criteria
* Beck depression test- to evaluate patient's ability to be influenced by the lidoderm patch. performance above 24 points is an exclusion criteria the participant will sign on an informed consent form and fulfill a demographic and personal details form.
the participant will undergo ear investigation to exclude ear inflammation, perform audiometry and tinnitus characteristic test to prove sensorineural hearing loss and to get details about the tinnitus characteristics. then the participant will fill 4 questionnaires that reflect the tinnitus loudness and show how much the participant does suffer from this conditions.
1. tinnitus handicap inventory.which estimates the degree that tinnitus affects patients life. it contains 25 questions . The minimum score is 0 and the maximum is 100.
2. Pittsburgh sleep quality index - A 9 questions exam that measures the quality of sleep. the range of results goes between 0-24. The higher the score- the worse is the quality of sleep.
3. visual analogue scale (VAS) for tinnitus subjective loudness evaluation (how much the patient evaluates the loudness of the tinnitus)
4. visual analogue scale (VAS) for tinnitus severity evaluation. (patient's estimation of the amount that tinnitus causes him subjective suffering) Then the investigators will perform randomization: one group will get first the lidoderm patch and later that week the tegaderm patch, the other group will get first the tegaderm patch and later on the lidoderm patch.
Later that day (in the evening), the participant will come to the department (second visit) and the ear nose and throat (ENT) doctor will attach 3 patches on his back for 12 hours (either lidoderm or tegaderm patches).
The participant will be instructed to call the chief investigator When any kind of side effect occurs (topical/ systemic).
in the next morning the participant will come back to our department. (third visit) he will-
1. fill the 4 questionnaires (tinnitus handicap inventory, pittsburgh sleeping scale, VAS severity scale and VAS loudness scale)
2. blood test for lidocaine serum level check will be carried out by a nurse that is authorized to perform blood tests.
3. removal of the patches from the patient's back. 60 hours after the third visit, the participant will attend our department (forth visit). An ENT doctor will attach 3 patches to his back (the second type of patches: participant that had already in the previous visit lidoderm patches will now have the tegaderm patches and vice versa). 12 hours later the participant comes back for his fifth visit. The same 3 steps that were performed in the third visit will be performed again (4 questionnaires, patches removal, blood test for lidocain serum determination).
The investigators hypotheses that lidoderm patches decreases tinnitus as can be estimated by the score of the 4 questionnaires that measure tinnitus aspects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. lidoderm patches first
29 tinnitus patients treated first with 3 patches of lidoderm for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 neutral patches (containing no drug) attach to their back for 12 hours.
after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches.
Lidoderm patch (Lidocaine 5% patch)
The investigator will attach the patches on the patient's back for 12 consecutive hours.
tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch
blood test- serum lidocain levels
each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.
the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests.
Hearing tests
each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
2. tegaderm patches first
29 tinnitus patients treated first with 3 patches of tegaderm (neutral patch containing no drug) for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 lidoderm patches attach to their back for 12 hours.
after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches.
Tegaderm patch. (neutral patch, containing no drug)
The investigator will attach the patches on the patient's back for 12 consecutive hours.
tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch
blood test- serum lidocain levels
each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.
the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests.
Hearing tests
each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidoderm patch (Lidocaine 5% patch)
The investigator will attach the patches on the patient's back for 12 consecutive hours.
tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch
Tegaderm patch. (neutral patch, containing no drug)
The investigator will attach the patches on the patient's back for 12 consecutive hours.
tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch
blood test- serum lidocain levels
each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.
the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests.
Hearing tests
each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients that are treated for tinnitus( psychological treatment, hearing aid, drugs, sound generator) or were treated in the last month
* sensitivity to amide anaesthetic
* known hepatic failure
* usage of antiarrhythmic drugs of type 1
* history of seizures
* pregnancy/ lactating
* dermatologic problems in the back
* any patients that develops during the trial local/ systemic symptoms such as rash, pain, itching, fever, nervousness,palpitations will be omitted from the study
* beck depression score of \>21
* MMSE test \<24
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Avi Shupak, MD
Role: STUDY_DIRECTOR
"LIN" MEDICAL CENTER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Haemek Medical Center
Afula, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-52
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.